Cybin Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Michael Halstead

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	4.9yrs
Yönetim Kurulu ortalama görev süresi	5.1yrs

Son yönetim güncellemeleri

Recent updates

Yeni Anlatı • Mar 20

Cybin Set to Revolutionize Psychedelic Therapy with CYB003's Promising Results

It sounds like Cybin (CYBN) is gaining serious traction in the psychedelic therapy space! Guggenheim’s $35 price target is pretty aggressive, considering the stock is currently trading at a fraction o

CEO

Michael Halstead (53 yo)

less than a year

Görev süresi

Mr. Michael I. Halstead, J.D., serves as Chief Executive Officer at Cybin Inc. since August 3, 2026. He is President at Intra-Cellular Therapies, Inc. since March 19, 2024 and had been its General Counsel...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Eric So	Co-Founder	5.8yrs	US$13.57m	6.18% CA$ 81.3m
Paul Glavine	Co-Founder	no data	US$13.56m	6.14% CA$ 80.6m
Greg Cavers	Chief Financial Officer	5.8yrs	US$1.22m	0.17% CA$ 2.3m
Aaron Bartlone	Chief Operating Officer	3.2yrs	US$1.22m	0.31% CA$ 4.0m
Amir Inamdar	Chief Medical Officer	4.9yrs	US$1.32m	0.31% CA$ 4.0m
Michael Halstead	Chief Executive Officer	less than a year	Veri yok	Veri yok
John Kanakis	Co-Founder	no data	US$1.19m	Veri yok
Alex Nivorozhkin	Chief Scientific Officer	5.8yrs	Veri yok	Veri yok
Lori Challenger	Chief Compliance	4.9yrs	Veri yok	Veri yok
Gabriel Fahel	Chief Legal Officer & Corporate Secretary	5.8yrs	US$1.12m	0.24% CA$ 3.2m
Sara Somerset	Chief Communications Officers	no data	Veri yok	Veri yok
Regina Donohue	Chief People Officer	less than a year	Veri yok	Veri yok

4.9yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: HELP 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Eric So	Co-Founder	5.8yrs	US$13.57m	6.18% CA$ 81.3m
Paul Glavine	Co-Founder	5.8yrs	US$13.56m	6.14% CA$ 80.6m
Robert S. Langer	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok
Theresa Firestone	Lead Independent Director	5.1yrs	US$239.50k	0.11% CA$ 1.4m
Freda Lewis-Hall	Independent Director & Chair of Scientific Advisory Committee	less than a year	US$339.01k	0.16% CA$ 2.2m
Mark Lawson	Independent Director	5.8yrs	US$239.50k	0.21% CA$ 2.8m
Grant Froese	Independent Director	5.8yrs	US$224.50k	0.21% CA$ 2.8m
Stephen Brannan	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok
Andrew Cutler	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok
Suresh Durgam	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok
Eric Hoskins	Independent Director	5.8yrs	US$224.50k	0.21% CA$ 2.8m

5.1yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: HELP 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.1 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/09/14 21:47
Gün Sonu Hisse Fiyatı	2026/09/11 00:00
Kazançlar	2026/06/30
Yıllık Kazançlar	2026/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Cybin Inc. 15 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
James Molloy	Alliance Global Partners
David Martin	Bloom Burton & Co.
Sumant Satchidanand Kulkarni	Canaccord Genuity

Cybin Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Co-Founder recently bought CA$1.7m worth of stock

Chief Operating Officer recently sold CA$504k worth of stock

High number of new directors

Helus Pharma Announces Management Changes

Cybin Inc., Annual General Meeting, Sep 22, 2026

Chief Financial Officer recently sold CA$609k worth of stock

Recent updates

Co-Founder recently bought CA$1.7m worth of stock

Chief Operating Officer recently sold CA$504k worth of stock

High number of new directors

Helus Pharma Announces Management Changes

New major risk - Financial position

New minor risk - Share price stability

Cybin Inc., Annual General Meeting, Sep 22, 2026

Helus Pharma Completes Enrollment In APPROACH Phase 3 Pivotal Study Of HLP003 In Adjunctive Treatment Of Major Depressive Disorder

Chief Financial Officer recently sold CA$609k worth of stock

Cybin Inc. has completed a Follow-on Equity Offering in the amount of $50.000008 million.

Helus Pharma Provides Update On Approach Phase 3 Trial Enrollment Progress

Helus Pharma Announces Scientific Advisory Board Appointments

New minor risk - Share price stability

Helus Pharma Announces CEO Changes Effective April 20, 2026

Helus Pharma Appoints Dr. Ken Kramer as Senior Vice President, Medical Affairs, Effective April 16, 2026

Helus Pharma Announces Appointment of Jill Conwell as Chief People Officer, Effective on March 12, 2026

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

Helus Pharma Appoints Freda Lewis-Hall to Board of Directors and Chair of the Scientific Advisory Committee

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2A Trial of Spl026 in Major Depressive Disorder

Helus Pharma Appoints Michael Cola as Chief Executive Officer, Effective February 10, 2026

Cybin Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Shareholder dilution

Cybin Inc. to Report Q2, 2026 Results on Nov 13, 2025

Cybin Inc. has completed a Follow-on Equity Offering in the amount of $175.009911 million.

Cybin Inc. has filed a Follow-on Equity Offering in the amount of $175.009911 million.

Cybin Inc. Highlights Upcoming Clinical Milestones

Cybin Inc. Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Insider recently bought CA$100k worth of stock

Cybin Inc. Announces Chief Executive Officer Changes

Cybin Inc. Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Inc. Announces George Tziras Not Standing for Re-Election

New major risk - Financial position

Cybin Inc. Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Inc. Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

New minor risk - Shareholder dilution

No longer forecast to breakeven

Cybin Inc. announced that it expects to receive $500 million in funding from High Trail Special Situations LLC

Cybin Inc., Annual General Meeting, Aug 18, 2025

Cybin Inc. Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Cybin Inc. Announces Additional U.S. Patent Supporting Its Cyb003 Therapy Program in Phase 3 Development for Major Depressive Disorder

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Cybin Set to Revolutionize Psychedelic Therapy with CYB003's Promising Results

Cybin Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Shareholder dilution

Cybin Reports Positive Phase 2 Data for Cyb003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

New minor risk - Profitability

No longer forecast to breakeven

Cybin Initiates PARADIGM Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Cybin Inc. Announces Executive Appointments

Cybin Inc. Provides Corporate Update on Upcoming Clinical Milestones

Insufficient new directors

Forecast to breakeven in 2027

Cybin Inc. Announces the Realignment of the Composition of Governance and Nominating Committee, and Compensation Committee

Cybin Inc., Annual General Meeting, Aug 27, 2024

Co-Founder recently bought CA$87k worth of stock

No longer forecast to breakeven

Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development

Forecast to breakeven in 2027

New minor risk - Share price stability

Cybin Inc. announced that it has received $150 million in funding from a group of investors

New minor risk - Profitability

Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder

Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

Cybin Inc. announced that it expects to receive $150 million in funding from a group of investors

Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder

Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028

Cybin Inc. Announces the Presentation of Four Posters At the American College of Neuropsychopharmacology Annual Meeting

Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses